A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD

NCT07583849 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

376

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD (Chronic Obstructive Pulmonary Disease)

Interventions

DRUG: HSK39004 Dry Powder Inhaler Simulant
DRUG: HSK39004 Dry Powder Inhaler-0.75mg

Sponsor

Haisco Pharmaceutical Group Co., Ltd.